Keros Therapeutics Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.02 | $-3.21 | $58.51 | -5.5% |
| 2022 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.03 | $-3.57 | $48.02 | -7.4% |
| 2023 | -0.1 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.03 | $-5.29 | $39.76 | -13.3% |
| 2024 | -0.2 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | 0.04 | $-5.28 | $15.83 | -33.4% |
| 2025 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.04 | $2.04 | $20.36 | 10.0% |
| 4-yr CAGR | n/m | 25.1% | 10.9% | n/m | n/a | n/m | 12.9% | n/m | -23.2% | avg -9.9% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | 0.0 | -0.1 | -278.6% | 0.0 | 0.2 | 1 | 1 | n/m | n/m |
| 2022 | 0.0 | -0.1 | -570.6% | 0.0 | 0.3 | 1 | 1 | n/m | n/m |
| 2023 | 0.0 | -0.2 | n/m | 0.0 | 0.3 | 1 | 1 | n/m | n/m |
| 2024 | 0.0 | -0.2 | -5,904.3% | 0.0 | 0.6 | 1 | 0 | n/m | n/m |
| 2025 | 0.2 | 0.1 | 29.6% | 0.0 | 0.3 | 1 | 1 | 6.9x | -3.75x |
| 4-yr CAGR | 86.7% | n/m | avg -23,745.6% | 98.2% | 5.7% | -13.3% | -18.5% | median 6.9x | avg -3.75x |
Revenue grew 86.7% a year and EBITDA n/m a year from FY2021 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 12.9% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 50% in FY2021 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 27% in FY2024 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.